Table D9. Medication adherence outcomes 1

| Author, YearTrial Name | Medication Adherence Outcome 1 | Description of Timing of Measurement of Adherence Outcome 1 | Data Source | N | Results |
| --- | --- | --- | --- | --- | --- |
| Bender et al., 20101NA | Percent adherence was determined by dividing the number of inhaler puffs taken by the number of puffs prescribed to be taken each day and then averaged over the 10-week interval | 10 weeks, measured once for entire period | Other  | G1: 25G2: 25 | Mean % (SD):G1: 64.5% (17.2)G2: 49.1% (16.8)F: 9.66p: .0032 |
| Berg et al., 19972NA | Compliance measured as a mean of number of events recorded on Chronolog inhaler vs. number of expected events based on self-report of prescription (SD)Source of data is a combination of self-report and MDI chronolog scores | Compliance calculated as a % each day at week 7 | Other  | G1: 31 G2: 24 | G1: 49 (31)G2: 32 (28)95% CI, NRp<0.05 |
| Berger et al., 20053NA | Discontinued use of Avonex | Assessed at 3 months | Self-report | G1: 172G2: 195 | G1: 2 (1.2%) discontinuedG2: 17 (8.7%) discontinued95% CI, NRp: 0.001 |
| Bogner et al., 20084NA | Depression adherence: % of prescribed doses taken; calculated as number of doses taken divided by the number of doses prescribed during the observation period multiplied by 100% - dichotomized with 80% threshold | Measured over 6 week study period for entire study period | MEMS | G1: 32G2: 32 | G1: 23 (71.9)G2: 10 (31.3)95% CI, p: .001 |
| Bogner et al., 20105NA | >80% adherence to an oral hypoglycemic agent | 4 times, biweekly beginning at baseline and ending at week 6 | MEMS | G1: 29G2: 29 | **BL**G1: 10 (34.5%)G2: 6 (20.7%) 95% CI, NRp: 0.19**EP at 6 weeks**G1: 18 (62.1%)G2: 7 (24.1%)95% CI, NRp: 0.004 |
| Bosworth et al., 20056V-STITCH | Change in proportion reporting overall medication adherence at 6 months between G1 and G2 | Last 6 months; 2 times (including baseline); 6 months | Self-report | G1: NRG2: NR | 0.007495% CI, -0.062 to 0.076p: NR |
| Bosworth et al., 20087TCYBBosworth et al., 20078TCYB Methods paper | Increase in self-reported adherence from baseline to 6 months | Last 6 months; 1 time; 6 months | Self-report | G1: 319G2: 317 | G1: +9% (63% to 72%)G2: +1% (67% to 68%)p=NR |
| Capoccia et al., 20049na | Adherenceto antidepressants - at 3 mo  | Defined as use ofantidepressants for at least 25 of thepast 30 days; measured at 3, 6, 9, 12 mos | Self-report | G1: NRG2: NR | G1: 85%G2: 81%95% CI, NRNot Significant |
| Carter et al., 200910NA | Percentage of patients with low self-reported medication adherence (i.e., score >3) | Measured twice, once at baseline & once at 6 month follow-up | Self-report | G1: 192G2: 210  | **BL (Mean %, SD)**G1: 17.3% (27.5)G2: 18.7% (22.0)95% CI, NR**6 month follow-up (Mean %, SD)**G1: 14.6% (25.4)G2: 14.7% (20.9)95% CI, NRP (within-group): 0.602 G2P (within-group): 0.979 G1 |
| Chernew et al., 200811NA | Medication Possession Ratio (MPR is number of eligible days in the quarter the person was in possession of the medication divided by the number of days in the quarter) | Measured in the pre and post periods (eight observations per patient during 2-year period) | Other  | **2004 (pre)**G1: range 919-1,245G2: range 3,596 - 4,185**2005 (post)**G1: range 1,056 - 1,306G2: range 3,535 - 4,072 | **Effect size (percent MPR Points)****ACE inhibitors/ARB** = 2.59, p<0.001**Beta-blockers** = 3.02, p<0.001**Diabetes drugs** = 4.02, p<0.001**Statins** = 3.39, p<0.001**Steroids** = 1.86, p<0.134 |
| Choudhry et al., 201012NA | Proportion of days covered (i.e., estimated number of days of medication available to each patient) - Change in level (i.e., immediate impact of copayment policy) | Measured monthly over the 24-month study period | Other  | Overall N: 52,631 G1: 2051G2: 779 G3: 38,174 G4: 11,627 | Statin usersAdjusted for differences in comorbidity & demographicsG1: 3.1% increase in monthly adherence over G3, with no subsequent change in slope95% CI, NRp: <0.05Matched by first fill date for eligible prescription in study timeframeG1: 2.6% increase over G3, with no subsequent change in slopep: <0.05Clopidogrel usersAdjusted (all patients)G2: 4.2% increase over G4, with no subsequent change in slope95% CI, NRp: <0.05 Matched by first fill date for eligible prescription in study timeframeG1: 6.6% increase over G4, with no subsequent change in slope95% CI, NRp: <0.05 |
| Choudhry et al., 201113 | Mean medication possession ratio (among all patients) | Number of days for which patients had a supply of each medication class available divided by the # days they were eligible for that medication. Patients who lost eligibility before randomization or who did not fill a prescription after randomization were considered to be nonadherent. | Prescription claims records | G1: 2845G2: 3010 | **All 3 medication classes**G1: 43.9 (33.7)G2: 38.9 (32.7)95% CI, 5.4 (3.6-7.2)p: <0.001**ACE inhibitor** **or ARB**G1: 41.1 (39.8)G2: 35.9 (38.1)95% CI, 5.6 (3.4-7.7)p: <0.001**Beta-blocker**G1:49.3 (37.5)G2: 45.0 (36.6)95% CI, 4.4 (2.3-6.5)p: <0.001**Statin**G1: 55.1 (37.7)G2: 49.0 (37.3)95% CI, 6.2 (3.9-8.5)p: <0.001 |
| Friedman et al., 199614NA | Antihypertensive medication adherence (total number of tablets, capsules, or patches dispensed minus the total number counted in the audit, divided by the number that should have been taken by each subject) | Change scores were computed using value at 6 months minus value at baseline | Pill count | G1: 133G2: 134 | Unadjusted change from BLG1: 2.4% mean increaseG2: 0.4% mean increasep= 0.29Adjusted change from BLG1: 17.7% mean increaseG2: 11.7% mean increasep= 0.03 |
| Fulmer et al., 199915NA | Percent of prescribed medication doses taken | Adherence was monitored during a 2-week pre-intervention phase, 6-week intervention phase (time 2), and 2-week post-intervention phase (time 3) | MEMS | G1: 17G2: 15G3: 18 | **Average compliance rates at BL**G1: 82%G2: 76%G3: 81%**Average compliance rates at time 3**G1: 84%G2: 74%G3: 57% (significantly decreased from baseline at p<0.04)95% CI, p: There was a statistically significant time effect during the course of the study from baseline to post-intervention (F=4.08, p<0.05). Over time, G1 and G2 showed enhanced compliance relative to G3. However, there was no significant difference between G1 and G2. |
| Grant et al., 200316NA | Difference from baseline to 3-month follow up in number of days in the last 7 that no doses were missed | 7 days; two measures; baseline and 3 months measures  | Self-report | G1: 61G2: 54 | G1: 0.1 (1)G2: 0.1 (0.4)95% CI, p: 0.8 |
| Guthrie et al., 200117First Myocardial Infarction (MI) Risk Reduction Program | Medication compliance survey: patient currently taking pravastatin as prescribed, % | NR; 2 times; 3 months | Self-report | G1: 3635G2: 913 | At 6 monthsG1: 79.7G2: 77.495% CI, NRp: NR |
| Hoffman et al., 200318NA | Percent adherence, first observation after 1 month of therapy | Patients with < 10 gap days in the initial month of therapy; measured once at 1 month | PRD | G1: 4899G2: 4665 | G1: 58.9G2: 57.495% CI, NRp: 0.136 |
| Hunt et al., 200819NA | Proportion of subjects reporting high medication adherence at study end | One time at end of study | Self-report | G1: 142G2: 130 | G1: 67% (N = 95/142)G2: 69% (N = 90/130)95% CI, NRp: 0.771 |
| Janson et al., 200921NA | Mean change % adherence; numerator was capped at the prescribed dosesper day to avoid overestimation of adherence to greater than 100% per day. Percent adherence (taken/prescribed) | Measured biweekly during 4-week intervention (T0-T1); measured at 4-week intervals for following 14 weeks of observation (T1-T2) | Other  | NR | **T0-T1**G1: -0.18G2: -1.40p: 0.72**T1-T2**G1: -4.28G2: -4.41p: 0.97 |
| Janson et al., 200320NA | ICS adherence (number of puffs recorded daily in the diary divided by the number of puffs prescribed) % (SD) Source of data was self-report supplemented by medication monitors | Assessed at baseline, and end of week 1, 2, 5, 7; time frame for baseline measurement was one week; time frame for final measurement NR | Other  | G1: 33 G2: 32 | G1: 91 (32) G2: 62 (38) 95% CI, NRp: NR |
| Johnson et al., 200623NR | Behavioral measure of non-adherence [Data source: 5-item survey measuring frequency of various form of non-adherence] | Last 6 months; 4 times every 6 months (0,6,12, and 18 months) | Self-report | G1: NRG2: NR | **BL**G1: in figure onlyG2: in figure only95% CI, NRP>0.05 **6 months**G1: in figure onlyG2: in figure only95% CI, NRP>0.05**12 months**G1: in figure onlyG2: in figure only95% CI, NRP<0.01**18 months**G1: in figure onlyG2: in figure only95% CI, NRP<0.001 |
| Johnson et al., 200622NR | Pre-action sample onlyReaching Action (A) or M (Maintenance) stage for adherence, % [Data source: complete case analysis evaluating Stage of Change] | Last 6 months; 4 times every 6 months (0,6,12, and 18 months) | Self-report | **BL**Overall N: 205G1: NRG2: NR**6 months**Overall N: 190G1: NRG2:NR**12 months**Overall N: 172G1: NRG2: NR**18 months**Overall N: 173G1:NRG2: NR | **BL**G1: in figure onlyG2: in figure onlyOR: NRp:NR**6 months**G1: 55.3%G2: 40.0%OR=1.80P<0.05**12 months**G1: in figure onlyG2: in figure onlyOR: NRp=0.057**18 months**G1: 56.0%G2: 37.8%OR: NRP<0.01 |
| Katon et al., 199524NA | % receiving adequate dosage of antidepressants for ≥30 days (details NR) | During continuation phase of treatment (3-7 months) | PRD | **Major depression group** N=91 **Minor depression group** N=126 | **Major depression group**G1: 87.8G2: 57.195% CI, NRp: <0.001 **Minor depression group**G1: 88.1G2: 47.895% CI, NRp: <0.001 |
| Katon et al., 199625NA | Medication adherence - telephone interview asking if they were still taking antidepressants and considered adherent if they reported taking medication at least 25 out of last 30 days | Measured at 1-month follow up | Other: self-report, verified with data from pharmacy refills, at 1 and 4 months the K statistic was 0.83 and 0.90 respectively.  | G1: 76 G2: NR | **Major Depression Group at 1-month follow up (% adherent)**G1: 85%G2: 63%p=0.06**Minor Depression Group at 1-month follow up (% adherent)**G1: 81%G2: 67%p=.13 |
| Katon et al., 199926NAKaton et al., 200227NA | Percent adherent to antidepressant medication | Patients report medication adherence; questions asked not specified. Considered adherent if medication taken for at least 25 of the previous 30 days; assessed at 1, 3, and 6 months(Reported in 9123) | Self-report | G1: 114G2: 114 | **At 1-month**G1: 77.4% G2: 69.2%Chi-square: 1.38p: 0.24**At 3 months**:G1: 78.6%G2: 62.1% Chi-square: 5.52p: 0.02**At 6 months**: G1: 73.2%G2: 50.5% Chi-square: 9.53p: 0.002 |
| Katon et al., 200128NALudman et al., 200329NAVan Korff et al., 200330NA | Percent patients who filled AD prescriptions (Katon et al.) | Measured at 3, 6, 9, 12 months | PRD | G1: NRG2: NR | **Across 12-months**: Adjusted OR forG1:G2, 1.9195% CI, (1.37, 2.65)p: < 0.001% patients (95% CI) **0-3 m**: G1: 80.7 (75.1-86.3)G2: 65.6 (58.8-72.4)**3-6m**:G1: 71.9 (65.5-78.2)G2: 58.2 (51.2-65.2)**6-9m**:G1: 68.4 (61.8-75.0)G2: 55.6 (48.5-62.7)**9-12m**:G1: 63.2 (53.3-70.0)G2: 49.7 (42.6-56.9) |
| Lee et al., 200631FAME | % medication adherence at 14 months (proportion of pills taken), mean (SD)  | Total timeframe of 6 month average (months 8-14); G1 - 3 pill counts every 2 months;G2 - 1 pill count at the end of 6 months | Pill count | G1: 83G2: 76 | G1: 95.5 (7.7)G2: 69.1 (16.4)95% CI, NRP<0.001 |
| Lin et al., 200632NA | Percentage of days nonadherent | Measured 2 times over a 12-month period | PRD | Oral hypoglycemic agent**BL**G1: 103 G2: 103**EP**G1: 103G2: 103ACE inhibitor**BL**G1: 54G2: 65**EP**G1: 59G2: 52Lipid-lowering agent**BL**G1: 50G2: 52**EP**G1: 54G2: 63 | Oral hypoglycemic agent**BL** (%) (Mean (SD))G1: 19.8% (21.3%)G2: 22.9% (24.0%)95% CI, NRp: NS**EP** (%) (Mean (SD))G1: 28.2% (28.9%)G2: 24.0% (24.7%)95% CI, NRp: <0.03ACE inhibitor**BL** (%) (Mean (SD))G1: 27.4% (27.1%)G2: 29.7% (29.3%)95% CI, NRp: NS**EP** (%) (Mean (SD))G1: 24.2% (22.7%)G2: 18.9% (17.4%)95% CI, NRp: NSLipid-lowering agent**BL** (%) (Mean (SD))G1: 29.3% (26.7%) G2: 24.5% (23.0%)95% CI, NRp: NS**EP** (%) (Mean (SD))G1: 28.8% (27.1%) G2: 27.7% (24.0%)95% CI, NRp: NS |
| Maciejewski et al., 201033 | Percent change in medication possession ratio (MPR) from baseline (adherence differences between G1 and G2)Unmatched analysis | 24 monthly assessments: 12 in the pre-intervention period and 12 in the post-period | Other  | **Diuretics**Overall N: NRG1: 15605G2: 9137**ACE Inhibitors**Overall N: NRG1: 14250G2: 7668**Statins**Overall N: NRG1: 18346G2: 10162**Beta Blockers**Overall N: NRG1: 11137G2: 6343**Calcium Channel Blockers**Overall N: NRG1: 7191G2: 4099**Metformin**Overall N: NRG1: 5077G2: 2826**ARBS** Overall N: NRG1: 7445G2: 4514**Cholesterol Absorption Inhibitors**Overall N: NRG1: 4019G2: 2291 | **Metformin**: 3.80% p: <0.001 **Diuretics**: 3.26% p: <0.001 **ACE inhibitors**: 2.87% p: <0.001 **Beta-blockers**: 2.48% p: <0.001 **Statins**: 1.81% p: <0.001 **Calcium-channel blockers**: 1.46% p: <0.01 **ARBS:** -0.10% p: NS **Cholesterol absorption inhibitors**: -1.04% p: NS |
| Mann et al., 201034The Statin Choice | % of participants with good adherence at 3 months using Morisky 8-item scale (NOTE: calculated % with "good adherence" without information re: how this was defined using the scale; other studies have used cut-off of <6) | Ever, yesterday, 2 weeks, sometimes (used Morisky 8-item scale which uses all these time frames); measured TWICE; at 3 and 6 months over the phone; | Self-report | G1: NRG2: NR | G1: NRG2: NR95% CI, p: No significant difference reported between groups for overall 70% with "good adherence" for whole group at 3 months |
| Montori et al., 201135 | Adherence: >80% days covered | Measured at 6 months | PRD | G1: 23G2: 19 | G1: 100%G2: 74%95% CI, NRp: 0.009 |
| Murray et al., 200736NA | "Taking Adherence": % of prescribed medication doses taken based on physician's prescription  | During intervention period (9 mos)Frequency: continuous daily MEMS monitoringDuration between measures: 12 to 24 hours, depending on med frequency | MEMS | G1: 122G2: 192 | Proportion (95% CI)G1: 78.8% (74.9-82.7)G2: 67.9% (63.8-72.1)Difference: 10.9% (5.0-16.7)p: NR  |
| Nietert et al., 200937NA | Time-to-refill (days) | NR | PRD | G1: 1018G2: 1016G3: 1014 | UnadjustedG1: Median (interquartile range or IR) = 108 (39-257)G2: Median (IR) = 116 (37-257)G3: Median (IR) = 106 (31-257) (257 represents a lower bound than 75th percentile because of amount of censoring present)95% CI, NRp: NRAdjustedG1: Hazard ratio (HR, 97.5% CI) = 0.93 (0.82-1.06)G2: HR, 98.3% CI = 0.87 (0.76-1.00)G3: HR, 95% CI = 0.93 (0.83-1.05)95% CI, NRp: NR |
| Okeke et al., 200938NA | Proportion of prescribed doses taken | Dosing aids were downloaded after the observational cohort period (capturing data for a 3 month period) and at the end of the RCT (capturing data for a 3 month period) | Other  | G1: 35G2: 31 | G1: adherence rate (SD) 0.73 (0.22)G2: adherence rate (SD) 0.51 (0.30)95% CI, NRp: 0.001 |
| Pearce et al., 200839Cardiovascular Risk Education and Social Support (CaRESS) Trial | Medication adherence (unspecified) | 3 times for G2, and 2 times for G1 and G3 over a 12-month period | Self-report | G1: 50 G2: 58 G3: 91 | **BL**High (%): G1: 50.0%G2: 29.8%G3: 41.8%Medium (%): G1: 42.0%G2: 63.2%G3: 49.5%Low (%): G1: 8.0% G2: 7.0% G3: 8.8%95% CI, NRP (G1 vs. G2 vs. G3): 0.1584P (G1 + G2 vs. G3): 0.4358**EP**High (%): G1: NR, G2: NR, G3: NRMedium (%): G1: NR, G2: NR, G3: NRLow (%): G1: NR, G2: NR, G3: NR |
| Powell et al., 199540NA | Medication possession ratio (MPR) | Refill data collected over a 9-month period | PRD | G1: 1993 G2: 2253 | **Overall** G1: 0.70 (0.23)G2: 0.70 (0.28) 95% CI, NRp: NR **Benazepril** (Mean (SD)) G1: 0.71 (0.25)G2: 0.72 (0.26) 95% CI, NRp: NR **Transdermal estrogen** (Mean (SD)) G1: 0.60 (0.32) G2: 0.58 (0.32) 95% CI, NRp: NR **Metoprolol** (Mean (SD)) G1: 0.74 (0.27) G2: 0.73 (0.28) 95% CI, NRp: NR **Simvastatin** (Mean (SD)) G1: 0.73 (0.26) G2: 0.70 (0.28) 95% CI, NRp: NR |
| Powers et al., 201168 | Self reported med adherence measured by Morisky scale | 3 months; 1 time; 3 months | Self-report | G1: 44G2: 45 | G1: 46%G2: 49%95% CI, NRp: 0.55 |
| Pyne et al., 201141HIV Translating Initiatives for Depression Into Effective Solutions (HITIDES) | Antidepressant regimen adherence - at 6 months;  | Each measurement is percentage adherence over previous 4 days (i.e. total number of prescribed pills taken divided by total number of prescribed; transformed to dichotomous outcome with cutpoint at >=80%). 3 measurements taken: baseline, 6-month and 12-months.  | Self-report | G1: 66G2: 72 | G1: 78.8%G2: 69.4%OR (95%CI): 1.60 (0.74 to 3.45)Adjusted OR (95%CI): 1.65 (0.75 to 3.62)Adjusted p: 0.22 |
| Rich et al., 199642NA | Overall compliance rates by method 1:percentage of pills taken correctly for each current medication determined by pill count at home visit by pharmacist or trained pharmacy assistant, then averaged | 30 days +/- 2 days after discharge; 1 time; NA | Pill count | G1: 80 G2: 76 | Overall: 84.6% +/- 15.1%G1: 87.9 +/- 12.0%G2: 81.1 +/- 17.2%95% CI, NRp: 0.003 |
| Rickles et al., 200543NA | % omitted antidepressant doses at 3 months | 2 measurements, each for 3 month time period | PRD | G1: 28 G2: 32 | N (Mean ± SD)G1: 28 (18.1 ± 23.5)G2: 32 (18.7 ± 22.1)NS |
| Ross et al., 200444NR | Medication adherence score (scored 0-4)[questions derived from Morisky] | NR; 3 times (including baseline); 6 months | Self-report | G1: NR G2: NR | **6 months**G1: 3.5G2: 3.4Difference (CI): +0.1 (-0.2 to 0.4) p: NR**12 months**G1: 3.6G2: 3.4Difference (CI): +0.2 (-0.1 to 0.6)p: 0.15 |
| Rudd et al., 200445NA | Rate of daily adherence (average number of days on which patient's took the correct number of doses as prescribed) at 6 months, mean (SD) | 1 day; daily ; 6 months | MEMS | G1: NRG2: NR | G1: 80.5% (23.0%)G2: 69.2% (31.1%)95% CI, NRp: 0.03 |
| Rudd et al., 200946NA | Mean score on adherence to treatments scale (0=best, 3=worst) | Measured at baseline, 6 and 12 months; self-report period NR | Self-report | **BL**G1: 51G2: 63**6 mos**G1: 49G2: 57**12 mos**G1: 48G2: 57 | **BL** mean (SD) score (0=best, 3=worst)G1: 0.40 (0.40)G2: 0.30 (0.37)**6 mos** mean (SD)G1: 0.23 (0.28)G2: 0.24 (0.32)**12 mos** mean (SD)G1: 0.17 (0.25)G2: 0.18 (0.30) |
| Schaffer et al., 200447NA | Pharmacy adherence % (days of medication dispensed (number of doses dispensed divided by daily dosage), divided by the number of days between refill and date of study visit ) for past 3 mo.  | Baseline, 3, 6 mo; 3 month time frame | PRD | G1: 11G2: 10G3:12G4:13 | % (SD)G1: Pre: 0.41 (0.42)3 mo: 0.53 (0.41)6 mo: 0.77 (0.24)G2:Pre: 0.32 (0.39)3 mo: 0.40 (0.32)6 mo: 0.48 (0.38)G3:Pre: 0.62 (0.34)3 mo: 0.73 (0.23)6 mo: 0.77 (0.24)G4 :Pre: 0.62 (0.40)3 mo: 0.42 (0.39)6 mo: 0.40 (0.44)BL-3 mo: G4 vs. G2 p = .4 G4 vs. G3 p = .02\* G4 vs. G1 p = .07  Pre-6 mo:G4 vs. G2 p = .17G4 vs. G3 p = .02\*G4 vs. G1 p = .04\* |
| Schectman et al., 199448NA | Answer at 2 months to interview question: "During the past week, how many doses of your medication have you missed?" | 7 day timeframe; 3 times total every 2 months | Self-report | **Niacin**:G1: 40G2: 40**BAS**:G1: 18G2: 22 | **Niacin**:G1: 76 +/-5G2: 77 +/- 695% CI, NRp: 0.85**BAS**: G1: 76 +/- 7G2: 60 +/- 995% CI, NRp: 0.14 |
| Schneider et al., 200849NA | Percentage of patients who had prescriptions refilled on time (±5 days of due date) | Calculated for all previous months at 6 month and 12 month follow-ups | PRD | G1: 47 G2: 38 | Mean (SD) G1: 80.4 (21.2) G2: 66.1 (28.0)95% CI, NRp: 0.12 |
| Schnipper et al., 200650NA | Medication adherence score on previous day | Whether patient took each medication exactly as prescribed on previous day | Self-report | G1: 92G2: 84 | 0-100, 100 represents complete adherence with all medicationsG1: 88.9 (0.71-1.00)G2: 87.5 (0.73-1.00)95% CI, NRp: 0.91 |
| Simon et al., 200651na | Filled prescriptions for at least 90 days of continuous antidepressant treatment at a minimally adequate dose | Measured once at 6 months | PRD | G1: 98G2: 97 | G1: 63 (64%)G2: 53 (55%)Chi-squared: 1.88p: .17 |
| Sledge et al., 200652NA | Medication adherence score | NR | Self-report | G1: NRG2: NR | G1: NRG2: NR95% CI, NRp: NR, text states that there was no significant difference between groups |
| Smith et al., 200853NR | Absolute increase in proportion of days covered per month for the entire follow-up period of 9 mos. | last 30 days; 9 times; 1 month apart | PRD | G1: 426G2: 410 | G1: 4.3% mean absolute increase in days covered per month compared to G2p= 0.04 |
| Solomon et al., 199854naGourley et al., 199855NA | Self-report of compliance comparing Visit 1 and Visit 5 in HTN group | Visit 1: baselineVisit 5: between 4 and 6 months  | Self-report | G1: 62G2: 70 | G1: Visit 1: 0.63 (SD 0.111)Visit 5: 0.23 (SD 0.054)CI: NRp <0.05G2: Visit 1: 0.60 (0.87)Visit 5: 0.61 (0.94)95% CI NR p NR |
| Stacy et al., 200956NA | 6 month point prevalence persistency: subject being in possession of a statin at the end of the 180-day observation period  | 6 months from baseline; 1 time; NA | PRD | G1: 253G2: 244 | G1: 70.4%G2: 60.7%Unadjusted OR (90% CI): 1.54 (1.13-2.10)Adjusted OR (90%CI): 1.64 (1.19-2.26)p: <0.05 |
| Taylor et al., 200357NA | Compliance  | At 12 months: Took ≥80% of all medications in past month (number of self-reported missed doses in past month of each med were divided by total prescribed doses for that month; %s for all meds were averaged together) | Self-report | G1: 33G2: 36 | Mean (SD) compliant patientsG1: 100G2: 88.9 (6.3)95% CI, NRp: 0.115 |
| Vivian et al., 200258NA | Compliance survey at 6 months: how often do you forget to take your medication (forgets>=once/wk)? (%) | Varied b/t groups; compliance measured in G1 at monthly visits, only measured at baseline and study end for G2 | Self-report | G1: 26 G2: 27 | G1: 68% G2: 48%95% CI, NRp: 0.252 |
| Waalen et al., 200959NA | Percentage of women using osteoporosis medication | Measured at 1 year and 30 days from entry into study using pharmacy database | PRD | G1: 109 G2: 102 | G1: 68.8% filled rxG2: 45.1% filled rx95% CI, NRp: <0.001 |
| Wakefield et al., 201160NA | Adherence [measured by 2 scales: Self-Reported Medication Taking Scale for HTN and DM validated regimen adherence scale addressing medication, diet, exercise, and BG testing] | 12 months; 1 time; NA | Self-report | G1: NRG2: NRG3: NR | G1: NRG2: NRG3: NR95% CI,NR p: NRAdherence improved in all 3 groups but no signifcant difference between groups |
| Weinberger et al., 200261NA | Single item indicator for proportion of noncompliance (Inui et al.) - adjusted OR at 12 months comparing 1)Pharm Care to peak flow monitoring and 2) Pharm care vs. Usual care | Assessed at baseline, 6 and 12 months; time frame is previous 2 months | Self-report | Overall N: 898G1: 356G2: 296G3: 246 | Pharm Care vs. Peak Flow monitoring (G1 vs. G2): aOR: 0.81 (0.58-1.12)Pharm Care vs. Usual Care (G1 vs. G3): aOR: 1.09 (0.80-1.49) |
| Weymiller et al., 200762Statin Choice Randomized TrialJones et al., 200963Statin Choice Randomized Trial | Post-intervention adherence (i.e., not missing any doses) in the last week | Measured once at 3 months after the intervention; measured only among those taking statins;  | Self-report | G1: 33 G2: 29 | G1: 31G2: 23Odds ratio: 3.495% CI, 1.5-7.5p: NR*<<Note: article reports number of people in each group who missed 1 or more doses in the last week, the numbers above are the people who did not miss a dose, i.e. those who were adherent>>* |
| Williams et al., 201064NA | Percent adherence to ICS at end of study; all adherence measures constructed as follows: linked electronic prescription information with ﬁll information from pharmacy claims data to estimate the number of days that a given ﬁll of an ICS would last (i.e., days supplied). This was calculated by dividing the canister size (i.e., puffs per canister) as derived from National Drug Codes in pharmacy claims by the dosage information (i.e., puffs per day). The calculated days of supply was then used to estimate adherence as a continuous measure of medication availability equal to the cumulative days of supply divided by the number of days of observation. This estimates the proportion of time that the patients took their medication.  | Once, end of study, measured for past 3 months of intervention | Other  | G1: 1335G2: 1363 | Mean +/- SE:G1: 21.3 +/- 2.5G2: 23.3 +/- 2.295% CI, NRp: .553 |
| Wilson et al., 201065Better Outcomes of Asthma Treatment (BOAT) | Medication acquisition at Year 1 - all asthma meds; Fill/reﬁll adherence was measured using a continuousmedication acquisition (CMA) index for each year, calculated as the total days’ supply acquired in a given year divided by 365 days | Follow-up year 1, continuous measure for entire year | PRD | G1: 204G2: 204G3: 204 | G1: 0.67G3: 0.46;p: 0.0001Group difference: 0.2195% CI, 0.13-0.28G1: 0.67G2: 0.59;p: .0029Group difference: 0.0895% CI, 0.01-0.15G2: 0.59G3: 0.46p: .0008Group difference: 0.1395% CI, 0.05-0.20 |
| Wolever et al., 201066NA | Morisky Adherence Scale | 6 months | Self-report | G1: 27G2: 22 | G1: Pre (Mean, SD) = 6.7 (0.96), Post (Mean, SD) = 7.2 (0.97)Change Over Time (P) = 0.004G2: Pre (Mean, SD) = 6.7 (1.25), Post (Mean, SD) = 6.9 (1.25)Change Over Time (P) = NS95% CI, NRp: NR |
| Zhang et al., 201067 (cont'd)NA | Medication Possession Ratio | Pre and post Part D | Other  | **Hyperlipidemia**G1: 418G2: 647G3: 5093G4: 3027**Diabetes**G1: 247G2: 304G3: 2214G4: 1253**Hypertension:**G1: 980G2: 1234G3: 8380G4: 4141A | **Hypertension** UnadjustedG1 Pre: 62.4; Post: 75.2G2 Pre: 81.1; Post: 82.6G3 Pre: 82.7; Post: 83.7G4 Pre: 85.1; Post: 84.0 Multivariate 2-year Part D Effect, estimate (95% CI)G1: 13.5 (18.6,25.0)G2: 2.6 (1.2, 4.1)G3: 2.5 (1.7, 3.2)G4 Ref % Change, Estimated Effects/pre Value (95% CI)G1: 21.8 (18.6, 25.0)G2: 3.2 (1.5, 5.0)G3: 3.0 (2.0, 3.9) |
| Zhang et al., 201067NA(Cont’d) | See above | See Above | See Above | See Above | **Hyperlipidemia** UnadjustedG1 Pre: 47.3; Post: 59.9G2 Pre: 57.6; Post: 63.3G3 Pre: 62.3; Post: 65.1G4 Pre: 74.4; Post: 73.0Multivariate 2-year Part D Effect, estimate (95% CI)G1: 13.4 (10.1, 16.8)G2: 7.3 (4.8, 9.8)G3: 4.4 (3.3, 5.6)G4 Ref% Change, Estimated Effects/pre Value (95% CI)G1: 28.5 (21.4, 35.8)G2: 12.6 (8.3, 17.0)G3: 7.1 (5.3, 9.1)**Diabetes**(Unadjusted)G1 Pre: 57; Post: 69.6G2 Pre: 77.3; Post: 76.2G3 Pre: 75.4; Post: 73.3G4 Pre: 81.8; Post: 78.2Multivariate 2-year Part D Effect, estimate (95% CI)G1: 17.9 (13.7, 22.1)G2: 4.5 (1.0, 7.9)G3: 3.6 (1.8, 5.3)G4 Ref% Change, Estimated Effects/pre Value (95% CI)G1: 31.4 (24.0, 38.8)G2: 5.8 (1.3, 10.3)G3: 4.8 (2.4, 7.1) |